Healthpeak Properties
Healthpeak Properties' revenue rose 4.5% to $2.8 billion in fiscal 2025. Its net margin was 2.5%, down from 9.0% a year earlier. Free cash flow was $357 million, up 7.0%. It paid out $946 million in dividends and buybacks, 265% of free cash flow. The diluted share count rose 2.9%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Revenue and margins
Net income and earnings per share
From fiscal 2016 to 2025, earnings per share fell 25.1% a year and net income 21.5% a year, as new shares raised the share count by 49% and diluted each share's earnings.
Returns on capital
Cash flow
Payouts and share count
Valuation
Two ways to value Healthpeak Properties yourself, both starting from its filings: a discounted cash flow model and the price-to-earnings method.
Discounted cash flow (DCF)
A discounted cash flow (DCF) model values a business as the cash it may generate in future, discounted back to today. The starting figures come from Healthpeak Properties' 10-K (or, for net cash and shares, its latest 10-Q) and the assumptions are yours: start from one of three example scenarios, then change any figure to see what it implies for a share, and how that compares with the last share price.
Value per share on three example scenarios, from Healthpeak Properties' fiscal 2025 free cash flow of $357M, net cash of −$9.4B at December 31, 2025 and 696 million diluted shares, from its filings. The scenarios are fitted to Healthpeak Properties: the base scenario's growth in years 1 to 5 is its revenue growth over the last 3 years, 11.0% a year; the cautious and optimistic ones are lower and higher, and growth in years 6 to 10 is halfway to the long-run rate. The base scenario's discount rate is 9% for a business of moderate risk (Health Care REITs); the cautious and optimistic ones use a point more and a point less. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target. A negative value means Healthpeak Properties' net debt is larger than what that scenario's cash flows are worth today.
- Last close, October 26, 2026
- $19.36
- Value on these assumptions, against the last close
- —
- Cash flows in years 1 to 10, valued today
- —
- Everything after year 10, valued today
- —
- Plus net cash
- —
- Share of value from after year 10
How the value changes with two assumptions
Price-to-earnings (P/E) method
Another common way to value a company is to multiply its earnings per share by a price-to-earnings (P/E) multiple: the number of years of today's earnings an investor pays for a share. A higher multiple usually means investors expect earnings to grow. Choose a multiple, for example from similar companies, to see the value it gives.
Value per share on three example scenarios, from Healthpeak Properties' earnings per share of $0.35 (over the last four quarters). Each grows earnings for a year at the cash flow scenarios' rates and applies a multiple to next year's earnings: 55.3×, the middle of Healthpeak Properties' own P/E today, its peers' median and its sector's median (Healthpeak Properties' own P/E today) for the base scenario, 20% less and more for the cautious and optimistic ones. The price is brought back a year at 10%, 9% and 8%. Select one to load it into the calculator. These are the model's arithmetic on those assumptions, not a forecast or a price target.
- Last close, October 26, 2026
- $19.36
- Value at this multiple, against the last close
- —
- Healthpeak Properties' P/E at the last close
- 55.3×
| Company | Last close | Earnings per share | P/E today |
|---|---|---|---|
| VentasVTR | $87.42 | $0.53 | 164.9× |
| American Healthcare REITAHR | $53.55 | $0.68 | 78.7× |
| Healthpeak PropertiesDOC | $19.36 | $0.35 | 55.3× |
| Omega Healthcare InvestorsOHI | $47.01 | $2.80 | 16.8× |
Balance sheet
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 158 | 72 | 118 | 120 | 468 |
| Debt incl. finance leases | 6,170 | 6,498 | 6,876 | 8,716 | 9,848 |
| Net debt (negative means net cash) | 6,012 | 6,426 | 6,759 | 8,596 | 9,380 |
| Net debt to EBITDA | 6.2x | 4.6x | 5.3x | 5.3x | 5.7x |
| Debt to equity | 0.9x | 1.0x | 1.1x | 1.0x | 1.3x |
| Interest coverage | 1.8x | 3.9x | 2.6x | 2.0x | 1.9x |
| Current ratio | — | — | — | — | — |
| Quick ratio | — | — | — | — | — |
Insider trades
Over the 12 months between October 27, 2025 and October 26, 2026, no insider bought Healthpeak Properties shares on the open market, and 1 insider sold $213,736.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| May 12, 2026 | Scott R BohnCDO and Head of Lab | Sold | 10,989 | $19.45 | $213,736 | Form 4 |
Piotroski F-score
The F-score counts how many of nine simple tests of profitability, funding and efficiency a company passed in a year (Piotroski, 2000). The more tests passed, the stronger the year: 8 or 9 is strong, 0 to 2 weak. Companies that report no gross profit are scored on the other eight.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Fail | Fail | Pass |
| Current ratio rose | — | — | — |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Pass | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Fail |
| F-score | — | — | — |
| Accruals ratio | −4.1% | −4.6% | −5.9% |
Compare
Put Healthpeak Properties side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Healthpeak Properties | FY25 | 4.5% | — | 12.7% | 3.2% | 5.7x | — | |
| American Healthcare REIT | FY25 | 9.2% | 18.4% | — | — | — | — | Compare |
| Ventas | FY25 | 18.5% | — | — | 3.4% | 5.6x | — | Compare |
| Omega Healthcare Investors | FY25 | 13.2% | — | 67.0% | 8.8% | 3.6x | — | Compare |
| Healthcare Realty Trust | FY25 | −6.9% | — | 10.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 2,129 | 1,848 | 1,191 | 1,240 | 1,645 | 1,896 | 2,061 | 2,181 | 2,700 | 2,822 |
| Revenue growth | 9.7% | −13.2% | −35.5% | 4.1% | 32.6% | 15.3% | 8.7% | 5.8% | 23.8% | 4.5% |
| Gross profit | 1,391 | 1,182 | 813 | 835 | 862 | 1,123 | 1,198 | 1,279 | 1,626 | 1,693 |
| Research and development | — | — | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — | — | — |
| Net income | 628 | 414 | 1,061 | 46 | 414 | 506 | 500 | 306 | 243 | 71 |
| Diluted EPS (US$) | 1.34 | 0.88 | 2.24 | 0.09 | 0.77 | 0.93 | 0.92 | 0.56 | 0.36 | 0.10 |
| Diluted shares (millions) | 467 | 469 | 475 | 489 | 531 | 539 | 539 | 547 | 676 | 696 |
| Cash flow | ||||||||||
| Cash from operations | 1,214 | 847 | 849 | 846 | 758 | 795 | 900 | 956 | 1,070 | 1,252 |
| Capital expenditure | 459 | 472 | 561 | 677 | 789 | 760 | 962 | 775 | 737 | 895 |
| Free cash flow | 755 | 375 | 288 | 169 | −30 | 36 | −62 | 182 | 334 | 357 |
| Dividends paid | 980 | 695 | 697 | 720 | 787 | 650 | 648 | 657 | 795 | 849 |
| Share buybacks | 9 | 5 | 3 | 5 | 10 | 13 | 68 | 6 | 191 | 97 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 23 | 14 | 17 | 18 | 17 | 18 | 26 | 14 | 16 | 14 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 95 | 55 | 54 | 80 | 44 | 158 | 72 | 118 | 120 | 468 |
| Debt incl. finance leases | 9,097 | 7,786 | 5,477 | 6,299 | 6,617 | 6,170 | 6,498 | 6,876 | 8,716 | 9,848 |
| Total assets | 15,759 | 14,088 | 12,719 | 14,033 | 15,920 | 15,258 | 15,771 | 15,699 | 19,938 | 20,336 |
| Total liabilities | 9,818 | 8,494 | 6,206 | 7,365 | 8,573 | 8,111 | 8,483 | 8,774 | 10,881 | 12,034 |
| Shareholders' equity | 5,548 | 5,301 | 5,944 | 6,085 | 6,734 | 6,516 | 6,655 | 6,350 | 8,401 | 7,500 |
| Margins and ratios | ||||||||||
| Gross margin | 65.3% | 64.0% | 68.2% | 67.3% | 52.4% | 59.2% | 58.1% | 58.6% | 60.2% | 60.0% |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | 29.5% | 22.4% | 89.1% | 3.7% | 25.1% | 26.7% | 24.3% | 14.0% | 9.0% | 2.5% |
| Free cash flow margin | 35.5% | 20.3% | 24.2% | 13.6% | −1.9% | 1.9% | −3.0% | 8.3% | 12.4% | 12.7% |
| Return on capital | 1.6% | 2.2% | 1.6% | 1.3% | 3.3% | 2.1% | 5.1% | 3.8% | 3.5% | 3.2% |
| Return on equity | 8.4% | 7.6% | 18.9% | 0.8% | 6.5% | 7.6% | 7.6% | 4.7% | 3.3% | 0.9% |
| Return on assets | 3.4% | 2.8% | 7.9% | 0.3% | 2.8% | 3.2% | 3.2% | 1.9% | 1.4% | 0.3% |
| Net debt to EBITDA | 8.6x | 9.1x | 8.2x | 9.7x | 6.6x | 6.2x | 4.6x | 5.3x | 5.3x | 5.7x |